AI Consensus Investment Thesis
ARGX: Argen-X Stock Price, Analysis & Forecast: 1 Year and 5 Year Targets
Argen-X: 1-Year and 5-Year Forecast Outlook and Rating
Argen-X (ARGX) has an immediate Strong Buy & Keep consensus AI recommendation, based on 14 AI analysts.
The 1-year target is €977 for , with +25.22% expected return (+25.22% including net dividends) and a STRONG BUY rating.
The 5-year target is €1,398 for , with +79.18% expected return (+79.18% including net dividends) and a BUY rating.
Latest available market price: EUR 780, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 0%. As of 2026-10-20.
Gross TTM: 0% · Two-year annualized gross: 0%.
Tax withholding assumption: 15% (NL). One-off special payments are excluded.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
Targets retain their original publication dates. Returns use the dated market close and the time remaining to each fixed target date. Current ratings also require fresh quotes and analysis, with more than 90 days remaining. Past targets have no forward return. Eligibility checked .
Argen-X Flagship Insight
Rare Disease Cash Flow Compounding Collides With Long Term Valuation Multiple Compression
High consensus confirms that subcutaneous autoantibody clearance drives substantial commercial operating leverage across chronic autoimmune indications. However, sharp divergence persists regarding whether robust earnings compounding can overcome valuation multiple compression caused by encroaching class competition, statutory payer rebate demands, and elevated long-term sovereign bond yields.
How were the Investment Thesis and Forecasts created?
14 AI advisors, guided by 9 analytical frameworks, contribute to the deep analysis by iPulse AI Engine.
Universal Investor (Polymath)
J.P. Morgan (Titan)
Superintelligence (Anthropologist)
Ray Dalio (Strategist)
Warren Buffett (Value Purist)
Machiavelli (Insider)
Sherlock Holmes (Whistleblower)
Elon Musk (Visionary)
Michael Burry (Vulture)
Ran across these frontier AI models
Google Gemini 3.8 Flash
OpenAI GPT-6 Astra
Anthropic Claude Opus 5
Latest published deep-analysis batch. Audit published forecasts in full transparency
Argen-X: forecast questions
What is Argen-X (ARGX)'s 1-year price forecast?
Argen-X's 1-year target is €977 for Sept 2027. The current AI rating is STRONG BUY. The expected return from the recorded close is +25.22%, or +25.22% modeled return including net dividends. Latest available market price: EUR 780, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is Argen-X (ARGX)'s 5-year price forecast?
Argen-X's 5-year target is €1,398 for Sept 2031. The current AI rating is BUY. The expected return from the recorded close is +79.18%, or +79.18% modeled return including net dividends. Latest available market price: EUR 780, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is the return basis?
Latest available market price: EUR 780, as of 20 Oct 2026. These are model projections, not guaranteed future prices.
How can I compare the AI opinions and audit past Argen-X forecasts?
14 AI analysts contribute to this publication. AI Opinions shows individual advisor forecasts and reasoning. Forecast History preserves earlier published batches; their figures describe their original publication, not today's outlook.
How does an AI-generated forecast for Argen-X differ from Wall Street analyst consensus?
Wall Street consensus aggregates estimates from human analysts. For listed companies, these typically include brokerage price targets, earnings forecasts and ratings. iPulse AI's forecast for Argen-X is a separate AI consensus generated through its own research workflow. Different inputs, forecast dates, assumptions and weighting can therefore produce different targets.
We believe the era of investment research conducted only by human analysts is drawing to a close. Frontier models increasingly match or exceed expert work on selected professional benchmarks, including evaluations covering financial analysis. Research on multi-model synthesis also shows that combining model responses can improve on a single model's output in the tasks studied.
iPulse AI generates transparent investment research and market forecasts using a swarm of AI configurations, analytical frameworks and frontier models. The workflow applies multiple verification, challenge and synthesis layers, with selective editorial review under Russlan Ramdowar, Editor-in-Chief. Published assumptions, disagreements and past forecasts remain available so readers can inspect the reasoning and audit outcomes.
For a research cycle covering 426 assets with 14 perspectives per asset, our internal workload model estimates approximately 114,000 hours of traditional analyst work. It assumes 16 hours per individual research report, 28 hours per consensus for synthesis and validation, plus shared data preparation. Parallel AI execution allows a deep-analysis cycle across hundreds of assets to complete in up to one day. The human-hours figure is an illustrative workload estimate, rather than measured time savings. Our research methodology explains the automated workflow.
Argen-X: Investment Thesis Summary
Dotted terms link to the glossary; hover or focus for a preview. Browse technical terms
If you invest €10,000 in Argen-X at the latest market close (20 Oct 2026): €17,918 by Sept 2031.
Returns use the same dated market close, fixed targets and remaining dividend period as the forecast table.
Benchmark comparison requires matching dated price and currency inputs.
The investment thesis centers on a commercial biopharmaceutical powerhouse transitioning into self-funding cash generation. High switching costs in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy anchor durable prescription volumes at gross margins near 89%. Because commercial sales infrastructure is largely fixed, incremental label expansions into adjacent rheumatological conditions generate powerful operating leverage, driving operating margins toward 35%. However, the equity is not cheap; reconciling half-year filings reveals true trailing multiples near 40x rather than screened 27x figures. Long-term returns depend entirely on operational earnings compounding outpacing inevitable valuation multiple contraction.
Key insights
- High patient switching barriers and subcutaneous autoinjector convenience protect core neurology revenues from immediate displacement by later-entering competitor molecules across outpatient clinics.
- Fixed commercial sales infrastructure absorbs adjacent autoimmune indications with minimal marginal expense, enabling free cash flow to compound faster than top-line revenue.
- Mandatory pharmacy benefit manager rebates and advancing rival FcRn inhibitors will compress terminal pricing, making volume expansion the primary earnings driver.
Argen-X: 5 Year Consensus Forecast
20 quarterly price targets, returns and rationale, with advisor range and benchmark
Forward returns are updated using the latest market close price of EUR 780, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 0%. As of 2026-10-20.
Gross TTM: 0% · Two-year annualized gross: 0%.
Tax withholding assumption: 15% (NL). One-off special payments are excluded.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
The consensus target follows an expert-weighted price path synthesized from 14 AI advisor opinions. See Opinion weights and rationale for the exact allocation and reasoning.
Forecast methodology and reference values
Published targets are anchored on 18 Sept 2026 at EUR 871. Original quarter-to-quarter target changes are retained. Forward returns use the remaining time to each fixed target date.
The pessimistic and optimistic advisor base cases are the lowest and highest published advisor base-case targets for each quarter. The advisor at either extreme can change between quarters. Benchmark values are in USD; FX values are exchange rates.
Scroll the table horizontally to read every column.
| Quarter | Evidence-Weighted Consensus Price Path | Individual Advisor Range & Reference Forecasts | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Consensus target (EUR) | Forecast quarter-to-quarter price change | Forward price return | Forward return incl. net dividends | Forecast rationale | Pessimistic Advisor Base Case (EUR) | Optimistic Advisor Base Case (EUR) | S&P 500 benchmark (USD) | FX (EUR/USD) | |
| €898 | +3.00% | +15.10% | +15.10% | Empasiprubart multifocal motor neuropathy data readout and initial subcutaneous CIDP adoption drive commercial optimism. Strong underlying volume growth is partially counterbalanced by acquisition cash digestion and elevated discount rates capping aggressive valuation multiples. | €837 | €950 | $750 | 1.14 | |
| €929 | +3.46% | +19.07% | +19.07% | Full-year 2026 audited financial reporting confirms expanding operating profitability and accelerating European commercial uptake. Reconciled earnings metrics demonstrate genuine operating leverage, though persistent sovereign bond yields prevent immediate valuation multiple expansion. | €870 | €1,016 | $736 | 1.13 | |
| €950 | +2.27% | +21.76% | +21.76% | Subcutaneous autoinjector rollout broadens outpatient access and reinforces patient adherence across core neurology indications. Commercial gains face minor friction from tariff pass-through uncertainties and seasonal reimbursement resets, keeping overall appreciation measured and orderly. | €896 | €1,077 | $743 | 1.13 | |
| €977 | +2.85% | +25.22% | +25.22% | International commercial expansion across Europe and Japan broadens recurring revenues, offsetting seasonal summer prescription slowdowns. Rising interest rate headwinds and cautious valuation discounting temper market enthusiasm, resulting in modest fundamental earnings-driven price progress. | €914 | €1,131 | $755 | 1.13 | |
| €1,012 | +3.58% | +29.71% | +29.71% | Late-stage clinical trial updates in rheumatology indications yield supportive efficacy markers, validating platform adjacency. Robust quarterly free cash flow generation reinforces balance-sheet resilience, attracting institutional capital into year-end portfolio positioning. | €878 | €1,222 | $776 | 1.14 | |
| €1,033 | +2.12% | +32.40% | +32.40% | Fiscal 2027 financial disclosures reveal operating margins consolidating above thirty percent. Sustained patient volume gains across established territories offset early payer rebate renegotiations, supporting steady multiple consolidation across major European exchanges. | €860 | €1,295 | $787 | 1.15 | |
| €1,065 | +3.05% | +36.50% | +36.50% | Regulatory approvals for adjacent neuromuscular indications broaden addressable commercial volume. Strong clinical switching barriers protect established core revenue streams, though advancing competitive pipeline disclosures from rival pharmaceutical developers introduce headline caution. | €886 | €1,347 | $803 | 1.15 | |
| €1,064 | -0.04% | +36.38% | +36.38% | Head-to-head competitive clinical disclosures and aggressive pharmacy benefit manager contracting talks generate tactical sentiment friction. Established physician loyalty cushions market share, limiting performance to narrow consolidation as investors weigh pricing sustainability. | €842 | €1,441 | $812 | 1.16 | |
| €1,101 | +3.46% | +41.12% | +41.12% | Relief following competitive data presentations and solid commercial execution in peripheral neuropathies restores buying momentum. Accelerating operating cash conversion and disciplined research expense management drive healthy quarterly valuation support into year-end. | €817 | €1,556 | $839 | 1.16 | |
| €1,129 | +2.52% | +44.71% | +44.71% | Full-year 2028 results confirm steady top-line compounding, while management demonstrates rigorous operational expense containment. Steady cash generation reinforces self-funding credentials, though valuation multiples face gradual downward pressure as organic percentage growth normalizes. | €800 | €1,650 | $851 | 1.17 | |
| €1,163 | +3.05% | +49.06% | +49.06% | Commercial launches across newly approved rheumatological indications unlock fresh volume streams, offsetting modest competitive pricing concessions. Subcutaneous convenience preserves high prescriber adherence, translating expanded patient onboarding into durable operating earnings growth. | €816 | €1,732 | $872 | 1.17 | |
| €1,182 | +1.59% | +51.50% | +51.50% | Routine annual payer formulary renegotiations and international pricing reference adjustments create mild gross-to-net drag. Resilient baseline prescription refills and expanding Asian market contributions cushion bottom-line earnings, enabling modest quarterly price advancement. | €784 | €1,801 | $886 | 1.18 | |
| €1,221 | +3.32% | +56.50% | +56.50% | Late-stage pipeline progression and maturing complement platform readouts reassure markets regarding long-term revenue durability. Healthier macroeconomic liquidity conditions provide modest multiple support, allowing accelerating net earnings to drive a solid quarterly advance. | €768 | €1,928 | $910 | 1.18 | |
| €1,245 | +1.93% | +59.57% | +59.57% | Annual 2029 financial disclosures highlight strong free cash flow conversion exceeding three billion dollars. Mature growth rates naturally moderate, prompting the valuation multiple to compress toward specialty pharmaceutical norms despite resilient cash generation. | €776 | €2,043 | $916 | 1.18 | |
| €1,254 | +0.76% | +60.73% | +60.73% | Next-generation pipeline candidates advance toward registrational milestones, partially dispelling long-term patent expiration anxieties. Competitor market entries in mature indications induce minor multiple compression, offset by steady cash accumulation on the balance sheet. | €752 | €2,145 | $937 | 1.19 | |
| €1,285 | +2.46% | +64.70% | +64.70% | Commercial execution across diversified indications maintains consistent cash flow generation, while high switching costs protect core neurology volume. Steady operational performance provides a reliable valuation floor, generating measured quarterly share price appreciation. | €760 | €2,231 | $947 | 1.19 | |
| €1,318 | +2.57% | +68.93% | +68.93% | Progress toward multi-indication corporate patient targets confirms operational maturity and robust recurring earnings. Sustained free cash flow accumulation sparks institutional speculation regarding potential shareholder capital returns, supporting positive equity performance into year-end. | €745 | €2,365 | $970 | 1.19 | |
| €1,346 | +2.13% | +72.52% | +72.52% | Full-year 2030 reporting illustrates elite biopharmaceutical operating margins near thirty-five percent. Exceptional cash conversion and pristine liquidity preserve defensive strength, though terminal multiple moderation limits quarterly price gains to underlying operational progress. | €760 | €2,483 | $980 | 1.19 | |
| €1,370 | +1.81% | +75.60% | +75.60% | Next-generation FcRn antibody development de-risks future franchise lifecycle transitions, mitigating biosimilar surveillance concerns. High recurring therapy demand and international market contributions sustain predictable cash flows, driving steady, low-volatility quarterly price appreciation. | €752 | €2,583 | $1,000 | 1.20 | |
| €1,398 | +2.01% | +79.18% | +79.18% | The five-year horizon concludes with the business firmly established as a profitable, cash-generative global immunology leader. Mature earnings compounding and defensive patent moats justify a solid valuation baseline, delivering dependable terminal equity compounding. | €760 | €2,686 | $1,012 | 1.20 | |
Show remaining 18 quartersShow first 2 quarters only
All 20 quarters are displayed in the table above.
Argen-X Stock Analysis & Scenarios Deep Dive
Argen-X: Alpha Gap & Repricing Catalysts
Market Narrative
What does the market currently expect? Market consensus frames the company as European biotechnology's premier growth compounder, extrapolating 60% historical sales expansion and treating multi-indication approval across systemic autoimmunity as practically assured. Sell-side commentary heavily anchors on an unadjusted screening multiple near 27 times earnings, largely dismissing pipeline execution setbacks, looming pricing pressure from rival FcRn developers, and statutory rebate extractions by health insurance payers.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd moderately underestimates value through an analytical misread of operating leverage, yet simultaneously overestimates near-term valuation cheapness due to screening data errors. While casual screens suggest a modest 27x trailing multiple on 7.6 billion dollars of revenue, reconstructed financial filings show true product revenue near 5.2 billion dollars, revealing a steeper 38x multiple. Crucially, the market fails to appreciate how fixed commercial infrastructure allows incremental indication revenues to convert into operating cash flows far faster than consensus anticipates.
Repricing Catalyst
What could make the market recognize and close that gap? Pivotal registrational readouts for empasiprubart in multifocal motor neuropathy alongside commercial sales disclosures demonstrating operating margins exceeding 30% serve as the decisive convergence catalyst cluster. Demonstrating clinical efficacy in non-FcRn biology breaks single-molecule dependency narratives, while widening cash generation will force sell-side analysts to lift multi-year operating cash-flow estimates over the twelve-to-twenty-four-month monitoring window.
Argen-X: Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed and Fear Sentiment
- Fear
- Volatility Regime
- Moderate
- Convergence Cycle Position
- Momentum
Reports agree on strong commercial momentum but diverge sharply on valuation risk. While optimistic views anticipate continued multiple stability, contrarian analyses warn that peak cyclical sentiment and oncoming competitive launches leave the equity vulnerable to multiple contraction.
Macro Regime Fit
Does the current market environment support the thesis? The macroeconomic setup is a mixed backdrop leaning slightly adverse for valuation multiples. A restrictive monetary policy environment with 5% sovereign bond yields exerts mechanical downward pressure on long-duration equity multiples. Conversely, inelastic clinical demand for life-altering autoimmune biologics and a fortress balance sheet holding over three billion dollars in net cash provide complete operational insulation from credit tightening.
Advisor Disagreement
What do our AI Advisors disagree about most? The core debate centers on starting valuation and competitive duration. Optimistic views model uninterrupted multiple expansion above 30x forward earnings, assuming subcutaneous convenience and prescriber stickiness permanently insulate the franchise from competitor entry. Conversely, skeptical assessments argue that true trailing earnings multiples sit near 40x rather than screened 27x figures, warning that incoming FcRn rivals and statutory payer rebates will compress operating margins and multiples toward mature specialty pharmaceutical norms. Observable quarterly net realized pricing trends and comparative Phase 3 data from rival molecules throughout 2027 will resolve this valuation divide.
Argen-X: Critical Influencing Factors
Near-certain positive forcesTop Drivers & Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Multi-indication autoimmune franchise label expansion | Innovation And Product | +34% | +52% | Systematic clinical label expansion of efgartigimod beyond generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy into rheumatology targets over 50,000 global patients. Because manufacturing batches and clinical foundations are already established, each incremental approval delivers high-margin volume that widens operating leverage, expanding long-term earning power across the five-year horizon. |
| Commercial operating leverage cash conversion | Operational Efficiency | +24% | +40% | Elite gross margins near 89% combine with an established global sales organization to drive rapid operational leverage. Having crossed structural profitability, selling expenses scale sub-linearly with new indication rollouts. This dynamic widens operating margins toward 35%, converting top-line commercial growth into accelerating free cash flow that compounds per-share intrinsic business value. |
| Subcutaneous convenience locks prescriber switching | Competitive Positioning | +20% | +28% | Widespread adoption of subcutaneous Vyvgart Hytrulo and prefilled autoinjectors displaces burdensome hospital infusions, achieving patient adherence above 85%. Once chronic neurological patients achieve clinical disease stability at home, neurologists face steep behavioural switching barriers against altering regimens. This entrenched prescriber loyalty protects core market share and insulates commercial volume from early competitor incursions. |
| Debt-free fortress balance sheet self-funding | Capital Allocation | +14% | +18% | Operating with virtually zero debt and substantial liquid reserves shields the business from credit contractions and elevated benchmark interest rates. Strong internal operating cash flows fully self-fund ten parallel registrational clinical trials and selective bolt-on acquisitions without equity dilution, preserving per-share capital compounding while competitors face capital-market financing constraints. |
Near-certain negative forcesTop Frictions & Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Rival FcRn class competitive encroachment | Competitive Positioning | -16% | -20% | Emerging neonatal Fc receptor antagonists from well-funded multinational pharmaceutical competitors contest core neurology indications. Although first-mover physician loyalty provides a strong defense, incoming alternatives force elevated promotional spending and aggressive hospital formulary rebating. This competitive crowding caps terminal net realized pricing per patient, tempering prospective operating margin expansion across outer forecast years. |
| Macroeconomic duration multiple compression drag | Macroeconomic And Macrofinancial | -15% | -4.0% | A higher-for-longer monetary regime featuring elevated sovereign bond yields imposes mechanical downward pressure on high-multiple growth equities. Trading at roughly 38-40 times normalized earnings, the equity faces inevitable multiple compression as discount rates penalize outer-year terminal cash flows. This duration tax absorbs a meaningful portion of underlying operational earnings growth over the horizon. |
| Payer utilization restrictions and statutory rebates | Regulatory | -13% | -16% | Intensifying healthcare budget scrutiny across the United States and Europe generates persistent downward pressure on specialty biologic reimbursements. Commercial insurers increasingly enforce step therapy, prior authorizations, and higher gross-to-net statutory rebates before approving chronic therapy. This administrative friction lengthens patient onboarding cycles, forcing unit volume to shoulder the entire top-line expansion burden. |
| Heavy registrational clinical research expenditure | Capital Allocation | -10% | -14% | Simultaneously advancing ten clinical-stage registrational programs across multiple rare diseases consumes over 1.5 billion dollars in annual research expenditures. High patient recruitment costs in rare cohorts, trial complexity, and ongoing post-acquisition integration outlays absorb substantial gross profit. This persistent reinvestment burden constrains near-term free cash flow yield expansion, deferring peak operating margin realization. |
Argen-X: What Could Break or Accelerate the Thesis
Event Risk Score: Moderate 47/100Asset-level relative pressure from clustered consensus frictions and tail risks. This is not the probability or risk score of an individual force.Plausible downside scenariosTail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Pivotal registrational clinical trial endpoint failure | 30% | -28% | A high-profile Phase 3 trial failure in an advanced pipeline indication, such as autoimmune myositis or multifocal motor neuropathy, would severely impair market confidence. Triggered by an inability to achieve statistical significance versus placebo, this setback would invalidate multi-franchise expansion assumptions, prompting immediate earnings write-downs, pipeline restructuring, and sharp equity multiple derating. |
| Severe postmarketing chronic infection safety signal | 16% | -38% | Commercial real-world pharmacovigilance identifying severe opportunistic infection clusters or paradoxical immune toxicities from prolonged systemic IgG clearance could trigger FDA black-box warnings or restrictive patient monitoring requirements. This regulatory intervention would paralyze new patient onboarding, accelerate prescriber hesitation, and trigger sharp downgrades to peak penetration across chronic neurological and rheumatological indications. |
Plausible upside scenariosTail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Empasiprubart pivotal breakthrough in motor neuropathy | 38% | +28% | Topline Phase 3 registrational success for empasiprubart in multifocal motor neuropathy would validate a second proprietary biologic platform targeting C2 complement inhibition. Triggered by statistically superior functional stabilization data, this breakthrough would establish an independent multi-billion-dollar rare disease franchise, dispelling single-molecule concentration concerns and prompting institutional analysts to aggressively raise long-term terminal valuation multiples. |
| Blockbuster registrational victory in Sjogrens syndrome | 32% | +32% | Positive pivotal Phase 3 registrational readouts for efgartigimod in primary Sjögren's syndrome would unlock a prevalent rheumatological population exceeding 300,000 addressable patients currently lacking approved targeted biologic therapies. This clinical triumph would expand peak addressable market potential by over four billion dollars annually, triggering substantial consensus earnings upgrades and accelerating enterprise free cash flow compounding. |
Company Financial AnalysisArgen-X: Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included. View latest Argen-X financials here.
Earnings and financials
The company has completed a historic turnaround, transitioning from heavy development-stage cash losses into substantial commercial profitability. Product revenue surged 84.7% in fiscal 2025 to 4.15 billion dollars, driven by rapid patient adoption of Vyvgart in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Reconstructed financial filings indicate true trailing product sales near 5.2 billion dollars through mid-2026. This explosive trajectory reflects genuine operating leverage rather than transient accounting windfalls. As recurring prescription volumes expand across specialized neurology clinics, operating income and cash flows have turned decisively positive. Patient demand for life-altering therapies remains highly predictable, providing a dependable foundation for long-term cash generation.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 4.2B | USD 1.3B | USD 876M |
| 2024 | USD 2.2B | USD 833M | USD -84.5M |
| 2023 | USD 1.2B | USD -295.1M | USD -464.1M |
| 2022 | USD 410.7M | USD -709.6M | USD -966.6M |
| 2021 | USD 528.3M | USD -408.3M | USD -728.2M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 33.8x | TTM | USD-normalized | EUR / USD |
| 2024 | 55.1x | TTM | USD-normalized | EUR / USD |
| 2023 | -- | TTM | Loss-making | EUR / USD |
| 2022 | -- | Annual | Loss-making | EUR / USD |
| 2021 | -- | Annual | Loss-making | EUR / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
Profitability trends highlight the remarkable economic power of proprietary biologic therapies. Gross margins remained stellar at 89.1% in fiscal 2025, reflecting exceptional pricing power and low incremental manufacturing costs per dose. Operating margins swung dramatically from negative territory in 2024 to 24.8% in 2025, climbing above 30% in mid-2026. This structural margin explosion stems from classic operating leverage. Because marketing and medical affairs teams cover concentrated specialist networks, sales overhead grows much slower than overall revenue. As new indications utilize the same sales infrastructure, incremental revenue drops straight to the bottom line, establishing a durable high-margin profile.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 1B | 24.8% | 32.4% |
| 2024 | USD -21.7M | -1.0% | 37.1% |
| 2023 | USD -425M | -34.7% | -24.1% |
| 2022 | USD -720.3M | -175.4% | -172.8% |
| 2021 | USD -348.7M | -66.0% | -77.3% |
Balance sheet and leverage
The balance sheet is designed as an impenetrable financial fortress, providing complete operational autonomy during volatile economic environments. Total assets stood at 8.68 billion dollars against 7.32 billion dollars in shareholder equity at year-end 2025. With a debt-to-equity ratio of just 0.01 and a current ratio exceeding 5.2, the company carries virtually no financial debt. This pristine solvency profile fully insulates operations from high central bank interest rates and credit market contractions. Even after committing 2.2 billion dollars in cash to acquire Forte Biosciences post-period, remaining liquidity comfortably funds late-stage clinical trials internally, eliminating the need for dilutive equity offerings or costly debt issuance.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Reported net cash / (debt) | Debt less (cash + short-term investments), calculated | Current ratio |
|---|---|---|---|---|---|
| 2025 | USD 47.2M | USD 4.4B | USD 3.4B net cash | USD -4.4B | 5.23x |
| 2024 | USD 37.7M | USD 3.4B | USD 1.5B net cash | USD -3.3B | 7.29x |
| 2023 | USD 20M | USD 3.2B | USD 2B net cash | USD -3.2B | 9.75x |
| 2022 | USD 12.4M | USD 2.2B | USD 788.3M net cash | USD -2.2B | 9.18x |
| 2021 | USD 11.5M | USD 2.3B | USD 1.3B net cash | USD -2.3B | 8.44x |
Reported net debt retains the source definition, which can deduct cash alone. Cash plus short-term investments is broader liquidity; the separately calculated column subtracts that full amount from total debt for the same fiscal period and currency. Reported net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
Management maintains an exceptionally capital-light operating structure, spending almost nothing on physical property, factories, or heavy machinery. In fiscal 2025, physical capital expenditure accounted for a negligible 0.15% of total revenue. Instead of building expensive manufacturing facilities, the company outsources biologic production to specialized contract development partners like Fujifilm. This disciplined strategy frees up operational cash to be reinvested straight into intellectual property and clinical trials. Research spending reached 1.42 billion dollars in 2025 to advance ten parallel registrational programs. While this clinical intensity absorbs substantial near-term cash, it maximizes return on invested capital by avoiding factory depreciation and fixed plant obsolescence.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 6.4M | USD 1.4B |
| 2024 | USD 1.7M | USD 949.3M |
| 2023 | USD 43.8M | USD 859.5M |
| 2022 | USD 103.8M | USD 663.4M |
| 2021 | USD 121.4M | USD 580.5M |
Behind the synthesisArgen-X: How Each Individual AI Forecaster Opinion Shapes the Global Consensus
This publication’s recorded synthesis allocated voting influence across 14 advisor opinions. The weights and rationales below are retained from that synthesis.
Across the submitted evaluations, an independently supported pattern confirms that commercial execution in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy generates substantial operating leverage over an established sales chassis. However, several reports uncritically propagate a flawed screening dataset claiming 7.6 billion dollars in trailing revenue and a 26.7x multiple, which incorrectly aggregates half-year cumulative totals. Primary SEC and corporate filings reveal true trailing product revenues near 5.2 billion dollars, placing the actual earnings multiple closer to 38x. The strongest contrarian case emphasizes that second-generation competitors and mandatory payer rebates will erode realized pricing just as higher benchmark yields depress growth multiples. Evaluations that forensically corrected the financial baseline and accounted for post-balance-sheet cash deployment, such as the Forte Biosciences acquisition, receive the highest weights. Overly euphoric trajectories assuming perpetual multiple expansion amid encroaching class competition are heavily downweighted to ensure realistic risk-adjusted synthesis.
All 14 opinions
Universal Investor AI
The Polymath
Anthropic Claude Opus 5 · 2026-07-24 releaseWeight: 16.0%
This rigorous evaluation stands out by forensically reconciling financial filings, debunking inflated screening database revenues, and identifying true valuation multiples near 40x. Its causal modeling soundly integrates Section 232 tariff considerations, duration drag, and competitive head-to-head friction, providing superior evidence-based discipline that justifies high relative weighting.
Universal Investor AI
The Polymath
OpenAI GPT-6 Astra · 2026-09-03 releaseWeight: 16.0%
This perspective provides exceptional analytical rigor by directly adjusting for the $2.2 billion Forte Biosciences acquisition and reconciling actual TTM product revenues to roughly $5.2 billion. Its disciplined recognition that multiple contraction will offset part of operational growth delivers superior causal consistency, warranting top weighting.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 9.0%
This report accurately recognizes that price-to-sales multiples face inevitable contraction from 8.5x toward 5.5x as the core franchise matures. Its realistic recognition of payer pushback and commercial step-therapy tempers top-line optimism, though it still relies on unadjusted trailing revenue datasets, earning a moderate weight.
Michael Burry AI
The Vulture
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 9.0%
This contrarian perspective provides a vital counterweight by rigorously modeling competitive erosion from next-generation FcRn entrants and aggressive pharmacy benefit manager rebate extraction. Even though its terminal volume stagnation is overly severe, its multiple contraction logic provides essential risk discipline, earning meaningful weight.
Ray Dalio AI
The Strategist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 8.0%
The evaluation correctly identifies all-weather operational insulation and non-discretionary autoimmune treatment demand amid restrictive monetary policy. Its analysis balances top-line growth with multiple compression risks. Nevertheless, reliance on aggregated database revenue metrics without reconciling half-year filing figures slightly impairs its causal foundation, justifying a controlled weight.
Sherlock Holmes AI
The Whistleblower
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 8.0%
This report delivers detailed operational analysis of neuromuscular prescribers, supply-chain commitments, and outsourced manufacturing dynamics. While it relies on unadjusted screening datasets, its careful treatment of partner royalties, manufacturing obligations, and commercial reimbursement hurdles provides grounded qualitative evidence, warranting a solid weight.
Elon Musk AI
The Visionary
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.0%
This assessment grounds switching costs in patient convenience and first-principles biological mechanics. However, it incorporates unadjusted trailing revenue data and understates the friction of payer step-therapy and statutory price concessions, justifying a moderate, well-calibrated weighting.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 5.0%
This perspective articulates valid switching costs in chronic neuromuscular care and capital-light biologic manufacturing. However, it relies on unadjusted screened sales metrics, uncritically accepts headline cash figures without deducting post-period commitments, and overstates terminal multiple resilience in a high-rate regime, warranting a modest weighting.
Niccolo Machiavelli AI
The Insider
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 5.0%
This analysis provides useful insights into orphan drug exclusivity perimeters and switching costs for subcutaneously treated patients. However, it assumes an aggressive 26x terminal forward multiple and overstates mid-term operating cash flow conversion while repeating unadjusted screening database numbers, warranting a tempered allocation.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 5.0%
The report offers sound qualitative commentary regarding sub-linear commercial cost scaling across adjacent neurological and rheumatological indications. However, it relies heavily on unverified database metrics, neglects post-period cash outlays for pipeline acquisitions, and adopts an optimistic stance toward multiple stability, justifying a reduced weight.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 4.0%
While effectively framing commercial operating leverage and prescriber stickiness, this report accepts screened financial metrics without reconciling underlying half-year SEC filings. Its expectation of forward multiple expansion to 32x normalized earnings conflicts with tighter monetary conditions and competitive class entry, necessitating a lower weight.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 4.0%
The analysis provides credible mechanics on autoinjector patient persistence and second-generation pipeline development. However, it models aggressive earnings compounding while repeating distorted trailing twelve-month revenue data and projecting multiple expansion that understates prospective pricing resistance, justifying a conservative weight.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 3.0%
Although capturing the commercial power of 89% gross margins, this report exhibits extreme optimism by projecting 104% returns. It relies on distorted screening figures and assumes sustained high multiples despite emerging class rivals and tightening reimbursement, requiring a heavy discount for uncritical assumptions.
J.P. Morgan AI
The Titan
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 2.0%
This report presents an overly promotional narrative projecting a tripling of equity value and $16.5 billion in revenue. It ignores multiple compression arithmetic, downplays competitor launches, and relies on distorted screened financials, warranting the lowest assigned weight due to poor analytical realism.
References & Context
Research Provenance
Analysis generated by iPulse AI Engine v7 using recorded market data, operating under the editorial standards and supervision of Russlan Ramdowar, Editor-in-Chief.
External references below are sources recorded by the researcher agents for this Argen-X forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher web33 available sources from this batch (73 recorded). The first 15 are shown below; expand to read the rest.
- ARGENX SE - Form CORRESP - FY2025 sec.gov
- Argenx stock holds near recent highs as Jefferies sticks to Buy rating ad-hoc-news.de
- argenx | argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis argenx.com
- argenx | argenx Completes Acquisition of Forte Biosciences, Inc. argenx.com
- argenx | argenx Highlights 2026 Strategic Priorities argenx.com
- argenx | argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update argenx.com
- argenx | argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update argenx.com
- argenx | argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update argenx.com
- argenx | argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline argenx.com
- Trump Administration Announces Section 232 Tariffs on Pharmaceuticals | Brownstein bhfs.com
- U.S. Pharma Tariffs And MFN Become Law After April 2 Update clinicalleader.com
- Check out argenx SE's stock price (ARGX) in real time cnbc.com
- ARGX Stock Quote Price and Forecast | CNN cnn.com
- FcRn Inhibitor Drug Market Size, Trends, Growth Report 2033 databridgemarketresearch.com
- A New Round in US Pharma Tariffs: What's at Play? - DCAT Value Chain Insights dcatvci.org
Show 18 more sources
- FcRn Inhibitor Market Outlook, Companies, Pipeline Drugs delveinsight.com
- argenx Q2 2026 Earnings Review - Finsee finsee.ai
- Argenx Reports 60% Jump in Vyvgart Sales in Q2 2026 Results globalbankingandfinance.com
- argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update globenewswire.com
- Vyvgart (Efgartigimod) Market Size | Industry Report, 2030 grandviewresearch.com
- Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis | Johnson & Johnson investor.jnj.com
- Argenx (ARGX) 2026 Feature: The Anatomy of a Biotech Powerhouse Transitioning to Profitability markets.financialcontent.com
- ARGX Stock Price Quote | Morningstar morningstar.com
- FcRn Inhibitor Market Projected for Robust Growth Through 2036 Across 7MM, Reports DelveInsight openpr.com
- argenx (ARGX) Q2 2026 Summary | Quartr quartr.com
- Liquidity and Capital Resources - argenx Annual Report 2025 reports.argenx.com
- Results of Operation - argenx Annual Report 2025 reports.argenx.com
- Shareholder Letter - argenx Annual Report 2025 reports.argenx.com
- Deadline Approaching for Companies Seeking Onshoring Deals to Reduce Section 232 Pharmaceutical Tariffs | Skadden, Arps, Slate, Meagher & Flom LLP skadden.com
- argenx SE (ARGX) Stock Price & Overview stockanalysis.com
- argenx Reports Half Year 2026 Financial Results and ... stocktitan.net
- argenx SE (ARGX) Stock News & Updates | StockTitan stocktitan.net
- ARGX Forecast — Price Target — Prediction for 2027 — TradingView tradingview.com
40 additional sources are recorded in this batch; their citation details are not available in this publication.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
Archived context covering 2025-01-01 to 2025-12-31. Its recorded scope includes technology and capital cycle; trade and industrial policy; monetary policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 90.8K bytes
- Words
- 13.3K words
- Characters
- 90.8K characters
- Est. tokens (characters ÷ 4)
- 22.7K tokens
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Archived context covering 2026-01-01 to 2026-09-20. Its recorded scope includes monetary policy and rates; geopolitics energy and shipping; trade and industrial policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 84.8K bytes
- Words
- 12.4K words
- Characters
- 84.8K characters
- Est. tokens (characters ÷ 4)
- 21.2K tokens
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental Context Passed as Input to the Models
Time range: Annual fiscal periods: 2014-12-31–2025-12-31, 12 periods; Quarterly fiscal periods: 2023-09-30–2026-06-30, 12 periods.
Currencies cited: EUR, USD (quote EUR; primary reporting USD; converted/valuation USD).
Show moreShow less
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
11 fieldscash · commonStockSharesOutstanding · netDebt · netReceivables · +7 more fields
Cash flow
4 fieldscapitalExpenditures · freeCashFlow · salePurchaseOfStock · totalCashFromOperatingActivities
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.